ANAPNEO THERAPEUTICS

Our Team

co-Founder and Chief Executive Officer

David L. McCormick

Ph.D., D.A.B.T.

David McCormick is co-Founder of Anapneo Therapeutics and serves as its Chief Executive Officer. Dr. McCormick has more than 30 years of experience in drug discovery and preclinical development, and has served as Principal Investigator on more than 50 programs supported by the National Cancer Institute and other branches of the National Institutes of Health. His group designed the family of compounds being developed by Anapneo Therapeutics, and he is directing preclinical toxicology, pharmacology, and other IND-enabling studies of Anapneo lead compounds. His management experience includes nearly 20 years as President/Director of IIT Research Institute (IITRI) in Chicago, where he leads a team of 110 scientists, technicians and support staff. He is also IITRI Professor of Biology at the Illinois Institute of Technology.

co-Founder and Chief Scientific Officer

Nanduri R. Prabhakar

Ph.D., D.Sc.

Nanduri Prabhakar is co-Founder of Anapneo Therapeutics and serves as its Chief Scientific Officer. Dr. Prabhakar is a world leader in oxygen sensing, physiologic responses to hypoxia, and mechanisms of respiratory control, and has published extensively in the field. He leads the research group that identified modulation of gasotransmitter signaling in the carotid body as a strategy to prevent and treat sleep apnea. Dr. Prabhakar is leading in vivo and in vitro efficacy evaluations and mechanism of action studies of Anapneo compounds. In addition to his role at Anapneo Therapeutics, Dr. Prabhakar serves as Harold Hines, Jr., Professor at the University of Chicago, where he leads the Institute for Integrative Physiology and the Center for Systems Biology of Oxygen Sensing.

co-Founder and Chief Executive Officer

David L. McCormick

Ph.D., D.A.B.T.

David McCormick is co-Founder of Anapneo Therapeutics and serves as its Chief Executive Officer. Dr. McCormick has more than 30 years of experience in drug discovery and preclinical development, and has served as Principal Investigator on more than 50 programs supported by the National Cancer Institute and other branches of the National Institutes of Health. His group designed the family of compounds being developed by Anapneo Therapeutics, and he is directing preclinical toxicology, pharmacology, and other IND-enabling studies of Anapneo lead compounds. His management experience includes nearly 20 years as President/Director of IIT Research Institute (IITRI) in Chicago, where he leads a team of 110 scientists, technicians and support staff. He is also IITRI Professor of Biology at the Illinois Institute of Technology.

co-Founder and Chief Scientific Officer

Nanduri R. Prabhakar

Ph.D., D.Sc.

Nanduri Prabhakar is co-Founder of Anapneo Therapeutics and serves as its Chief Scientific Officer. Dr. Prabhakar is a world leader in oxygen sensing, physiologic responses to hypoxia, and mechanisms of respiratory control, and has published extensively in the field. He leads the research group that identified modulation of gasotransmitter signaling in the carotid body as a strategy to prevent and treat sleep apnea. Dr. Prabhakar is leading in vivo and in vitro efficacy evaluations and mechanism of action studies of Anapneo compounds. In addition to his role at Anapneo Therapeutics, Dr. Prabhakar serves as Harold Hines, Jr., Professor at the University of Chicago, where he leads the Institute for Integrative Physiology and the Center for Systems Biology of Oxygen Sensing.

Collaborating Institutions

University of Chicago
IIT Research Institute

CONTACT US HERE

14 + 12 =